|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.4400 - 0.4999|
|52 Week Range||0.3000 - 5.7600|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.23|
NEW YORK and TORONTO , March 16, 2020 /CNW/ - iAnthus Capital Holdings, Inc . ("iAnthus" or the "Company") (CSE: IAN, OTCQX: ITHUF), which owns, operates, and partners with best-in-class ...
This is the Company's third dispensary to open in New York and 31st system-wide. Staten Island is located at 338 New Dorp Lane, Staten Island, New York , 10306, and is the only Registered Organization serving Staten Island's population of close to 500,000.
Concentrates, including vape cartridges and syringes, contribute approximately 40% of GrowHealthy's revenue year-to-date. Based on early results, RSO appears to be almost entirely incremental to GrowHealthy's concentrate sales. According to the Florida Office of Medical Marijuana Use Weekly Updates, the Company sold approximately 15 million milligrams of THC in the four-week period ending March 6, 2020 , compared to approximately 9.5 million milligrams sold in the period ending February 7, 2020 , representing a 55% increase in volume sold.
The Company will host a conference call for financial analysts and investors at 8:30am ET on Tuesday, April 7, 2020 to discuss the Company's fourth quarter and full year 2019 results. Founded by entrepreneurs with decades of experience in operations, investment banking, corporate finance, law and health care services, iAnthus provides a unique combination of capital and hands-on operating and management expertise.
NEW YORK and TORONTO , Feb. 27, 2020 /CNW/ - iAnthus Capital Holdings, Inc . ("iAnthus" or the "Company") (CSE: IAN, OTCQX: ITHUF), which owns, operates, and partners with best-in-class ...
The 3,850 square foot store, located at 338 New Dorp Lane, will be the only Registered Organization serving the borough of Staten Island's population of close to 500,000. Staten Island is scheduled for March 26, 2020 .
MPX New Jersey, an affiliate of iAnthus, is the ninth Alternative Treatment Center (ATC) in the state to receive a cultivation permit. This marks the tenth state in iAnthus' operational footprint. On February 3, 2020 , the New Jersey Department of Health issued MPX New Jersey a permit to cultivate at the Company's Pleasantville cultivation facility.
The Company passed its final Massachusetts Cannabis Control Commission ("CCC") inspection at the Holliston, Massachusetts facility in December and has been approved to commence operations for adult-use cultivation and production, effective Monday, January 27. The license allows the Company to directly supply the state's rapidly growing adult-use cannabis market with high-quality flower, concentrates, edibles, and other products.
Individual and institutional investors as we ll as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations NEW YORK , Jan. 13, 2020 /CNW/ - Virtual Investor Conferences ...
New store marks the Company's twelfth location in network of Florida cannabis dispensaries NEW YORK and TORONTO , Jan. 8, 2020 /CNW/ - iAnthus Capital Holdings, Inc . ("iAnthus" or the "Company") ...
Chief Executive Officer, Hadley Ford, to provide company update and outlook on Tuesday, January 14 at 3 p.m. During the conference, Hadley Ford, CEO of iAnthus, will provide an update on the Company's current operations and outlook for 2020. The Company will also be hosting one-on-one meetings and breakout sessions over the course of the three-day conference.
On December 12, 2019, the Massachusetts Cannabis Control Commission ("CCC") amended its quarantine of all cannabis vaping products, including allowing state-licensed operators to resume the sale of vaping products, which are manufactured on or after December 12th and tested for vitamin E acetate and other contaminants, including heavy metals. The CCC also requires a new product insert and general warning for all vaping products. As previously stated, the Company has never used vitamin E acetate in the production of its vaping products and therefore does not foresee a delay, other than potential testing backlogs, in making its vaping products available to patients as soon as possible.